FR 128998

a platelet activating factor (PAF) receptor antagonist; structure given in first source

Also Known As:

1-benzyl-10-(3-pyridylmethyl)-7-thia-10-azaspiro(5,6)dodecan-11-one 7,7-dioxide hydrochloride; FR-128998; FR128998

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Spiro Compounds: 2
      - FR 128998: 4
Polycyclic Compounds: 6
- Spiro Compounds: 2
  - FR 128998: 4

Experts

1.	Iwazaki, S: 2 articles (01/2001 - 11/2000)
2.	Kawashima, Y: 2 articles (01/2001 - 11/2000)
3.	Matsumoto, K: 2 articles (01/2001 - 11/2000)
4.	Morishita, Y: 2 articles (01/2001 - 11/2000)
5.	Ohwada, S: 2 articles (01/2001 - 11/2000)
6.	Sunose, Y: 2 articles (01/2001 - 11/2000)
7.	Takeyoshi, I: 2 articles (01/2001 - 11/2000)
8.	Tsutsumi, H: 2 articles (01/2001 - 11/2000)
9.	Aiba, Masaaki: 1 article (01/2001)
10.	Iwazaki, Shigeru: 1 article (01/2001)

Related Diseases

1.	Ischemia 01/01/2001 - "FR128998 ameliorates liver injury in extended liver resection with ischemia in dogs." 11/01/2000 - "FR128998 ameliorates liver injury after ischemia-reperfusion with extended liver resection in dogs." 01/01/2001 - "FR128998 provides a protective effect for liver parenchyma and sinusoidal endothelial cells during extended liver resection with ischemia."
2.	Disseminated Intravascular Coagulation 06/13/1994 - "In addition, FR128998 attenuated the increase in serum tumor necrosis factor (TNF) which appeared during the initial stage of disseminated intravascular coagulation. " 06/13/1994 - "Effect of FR128998, a novel PAF receptor antagonist, on endotoxin-induced disseminated intravascular coagulation." 06/13/1994 - "The changes in coagulation parameters of disseminated intravascular coagulation, i.e., prolongation of activated partial thromboplastin time and elevated levels of fibrinogen/fibrin degradation products, were also prevented by the treatment with FR128998. " 06/13/1994 - "This study aimed to evaluate the effect of FR128998, (1s,6s)-1-benzyl-10-(3-pyridyl-methyl)-7-thia-10-azaspiro [5,6]-dodecan-11-one 7,7-dioxide hydrochloride, a novel platelet activating factor (PAF) receptor antagonist, on endotoxin lipopolysaccharide-induced disseminated intravascular coagulation in rats. "
3.	Reperfusion Injury 01/01/2001 - "FR128998 (a PAF Receptor Antagonist) Counters the Increased Pulmonary Vascular Resistance Associated with Ischemia-Reperfusion Injury in the Canine Lung."
4.	Thrombocytopenia (Thrombopenia) 06/13/1994 - "Simultaneous infusion of FR128998 (0.25 and 1.0 mg/kg/h) with lipopolysaccharide dose dependently inhibited thrombocytopenia, but not leukopenia. "
5.	Leukopenia 06/13/1994 - "Simultaneous infusion of FR128998 (0.25 and 1.0 mg/kg/h) with lipopolysaccharide dose dependently inhibited thrombocytopenia, but not leukopenia. "

Related Drugs and Biologics

1.	Platelet Activating Factor
2.	Lipopolysaccharides
3.	Endotoxins
4.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
5.	Fibrinogen (Factor I)
6.	Fibrin Fibrinogen Degradation Products